Status:
UNKNOWN
Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants
Lead Sponsor:
China Medical University Hospital
Conditions:
Infant, Premature
Leukomalacia, Periventricular
Eligibility:
All Genders
2-6 years
Phase:
PHASE1
PHASE2
Brief Summary
Periventricular leukomalacia (PVL) is one of the most common brain injuries that occur in preterm infants. Inflammation, hypoxia-ischemia, free oxygen radical formation and excitotoxicity are all know...
Detailed Description
Periventricular leukomalacia (PVL) is one of the most common brain injuries that occur in preterm infants. Inflammation, hypoxia-ischemia, free oxygen radical formation and excitotoxicity are all know...
Eligibility Criteria
Inclusion
- After informed consent is obtained, very preterm infants with gestational age of \< 32 weeks and admit to our NICU are eligible for enrollment.
Exclusion
- Genetically defined syndromes,
- Congenital malformations that adversely affect neurodevelopment.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2011
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00910234
Start Date
August 1 2009
End Date
July 1 2011
Last Update
May 29 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 400